Palmoplantar Pustulosis
4
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
3100%
On Market (1)
Approved therapies currently available
UP
Competitive Landscape
3 companies ranked by most advanced pipeline stage
UP
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program1
ImsidolimabPhase 2Monoclonal Antibody1 trial
Active Trials
Boehringer IngelheimINGELHEIM, Germany
1 program1
SpesolimabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
UCB PharmaBimekizumab
Boehringer IngelheimSpesolimab
Vanda PharmaceuticalsImsidolimab
Clinical Trials (3)
Total enrollment: 467 patients across 3 trials
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Start: Nov 2025Est. completion: Nov 2029300 patients
Phase 3Recruiting
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
Start: Sep 2020Est. completion: May 2023108 patients
Phase 2Terminated
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Start: May 2019Est. completion: Apr 202159 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 467 patients
3 companies competing in this space